Cochrane · systematic review · CD008492
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
Gogtay, N, Kannan, S, Thatte, UM, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 2 · 28.6%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings: ACT versus CQ
Population: Adults and children with uncomplicated P. vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Remaining parasitaemic at 24 hours Summary of findings: ACT vs CQ | RR 0.42 [0.36, 0.5] | 4 studies · 1652 participants | High |
Remaining febrile after 24 hours Summary of findings: ACT vs CQ | RR 0.55 [0.43, 0.7] | 2 studies · 990 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 Summary of findings: ACT vs CQ | RR 0.58 [0.18, 1.9] | 5 studies · 1622 participants | High |
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 Summary of findings: ACT vs CQ | RR 0.27 [0.08, 0.94] | 1 study · 376 participants | Low Downgraded: imprecision, indirectness |
Serious adverse events Summary of findings: ACT vs CQ | RR 1 [0.14, 7.04] | 5 studies · 1775 participants | High |
Summary of findings: DHA‐P versus alternative ACTs in high transmission settings with known CQ resistance
Population: Adults and children with uncomplicated P. vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 Summary of findings: DHA‐P vs alternative ACTs | RR 0.2 [0.08, 0.49] | 3 studies · 334 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 Summary of findings: DHA‐P vs alternative ACTs | RR 0.21 [0.1, 0.46] | 2 studies · 179 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Summary of findings: ACT vs CQ
Population: Adults and children with uncomplicated P. vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Remaining parasitaemic at 24 hours Summary of findings: ACT vs CQ | RR 0.39 [0.31, 0.48] | 3 studies · 1165 participants | High |
Remaining febrile after 24 hours Summary of findings: ACT vs CQ | RR 0.55 [0.43, 0.7] | 2 studies · 990 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 Summary of findings: ACT vs CQ | RR 1 [0.3, 3.39] | 4 studies · 1185 participants | High |
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56 Summary of findings: ACT vs CQ | no estimate extracted | NR | No studies |
Serious adverse events Summary of findings: ACT vs CQ | RR 1 [0.14, 7.04] | 4 studies · 1275 participants | High |
Summary of findings: DHA‐P vs alternative ACTs in high transmission settings with known CQ resistance
Population: Adults and children with uncomplicated P. vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 Summary of findings: DHA‐P vs alternative ACTs | RR 0.2 [0.08, 0.49] | 3 studies · 334 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 Summary of findings: DHA‐P vs alternative ACTs | no estimate extracted | NR | No studies |